An overview of the pharmacokinetics of polymer-based nanoassemblies and nanoparticles

Current Drug Metabolism

Volumn 14, Issue 8, 2013, Pages 832-839

  Zhao, Qing He ^a   Qiu, Li Yan ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Absorption; Distribution; Elimination; Metabolism; Nanomedicine; Pharmacokinetics; Polymer nanoparticles

Indexed keywords

CELL PENETRATING PEPTIDE; CHITOSAN; DEXTRAN; DOXORUBICIN; HYALURONIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; LIPOSOME; MACROGOL; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; POLOXAMER; POLYACRYLAMIDE; POLYACRYLIC ACID; POLYMER; POLYSTYRENE;

ACTIVE TRANSPORT; ARTICLE; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; HUMAN; NONHUMAN; PH; PHYSICAL CHEMISTRY; SURFACE CHARGE;

ABSORPTION; ANIMALS; HUMANS; NANOSTRUCTURES; POLYMERS; TISSUE DISTRIBUTION;

EID: 84887963669     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920021131400104     Document Type: Article

References (97)

1. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 70(1-2), 1-20.
2. Kataoka, K.; Harada, A.; Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev., 2001, 47(1), 113-131.
3. Discher, D.E.; Ahmed, F. Polymersomes. Annu. Rev. Biomed. Eng., 2006, 8, 323-341.
4. Lee, J.S.; Feijen, J. Polymersomes for drug delivery: Design, formation and characterization. J. Control. Release, 2012, 161(2), 473-483.
5. Anton, N.; Benoit, J.P.; Saulnier, P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J. Control. Release, 2008, 128(3), 185-199.
6. Gao, C.; Yan D. Hyperbranched polymers: from synthesis to applications. Prog. Polym. Sci., 2004, 29(3), 183-275.
7. Vinogradov, S.V. Colloidal microgels in drug delivery applications. Curr. Pharm. Des., 2006, 12(36), 4703-4712.
8. Yu, B.; Tai, H.C.; Xue, W.; Lee, L.J.; Lee, R.J. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol., 2010, 27(7), 286-298.
9. Qiu, L.; Zheng, C.; Zhao, Q. Mechanisms of drug resistance reversal in Dox-resistant MCF-7 cells by pH-responsive amphiphilic polyphosphazene containing diisopropylamino side groups. Mol. Pharm., 2012, 9(5), 1109-1117.
10. Edinger, D.; Wagner, E. Bioresponsive polymers for the delivery of therapeutic nucleic acids. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2011, 3(1), 33-46.
11. Bawa, R. Nanoparticle-based Therapeutics in Humans: A Survey. Nanotechnology Law & Business 2008, Summer 135-155.
12. Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med., 2012, 63, 185-198.
13. Raizada, A.; Bandari, A.; Kumar, B. Polymers in drug delivery: a review. Int. J. Pharm. Res. Dev., 2010, 2(8), 9-20.
14. Rowland, M.; Tozer, T.N. Clinical Pharmacokinetics-Concepts and Applications, 3rd ed.; Lippincott Williams and Wilkins: Philadelphia, PA, 1995, pp. 15.
15. Egan, W.J.; Lauri, G. Prediction of intestinal permeability. Adv. Drug Deliv. Rev., 2002, 54(3), 273-289.
16. Hathway, D.E.; Chasseaud, L.F. Processes of absorption, distribution, and excretion. In: Foreign Compound Metabolism in Mammals. Hathway, D.E., Ed.; Eyre & Spottiswoode Ltd. Thanet Press, Margate, 1970, 1, 1-33.
17. Rouser, G.; Nelson, O.J.; Fleischer, S.; Simon, G. In: 'Biological Membranes'; Chapman, D., Ed; Academic Press, London, 1968, p. 5.
18. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54(5), 631-651.
19. Ernsting, M.J.; Foltz, W.D.; Undzys, E.; Tagami, T.; Li, S.D. Tumor- targeted drug delivery using MR-contrasted docetaxel - carboxymethylcellulose nanoparticles. Biomaterials, 2012, 33(15), 3931-3941.
20. Li, S.D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm., 2008, 5(4), 496-504.
21. Igarashi, E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol. Appl. Pharmacol., 2008, 229(1), 121-134.
22. Pappo, J.; Ermak, T.H.; Steger, H.J. Monoclonal antibody-directed targeting of fluorescent polystyrene microsphere to Peyer's patch M cells. Immunology, 1991, 73(3), 277-280.
23. Florence, A.T.; Hillery, A.M.; Hussain, N.; Jani, P.U. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J. Control. Release, 1995, 36(1-2), 39-46.
24. Mathiowitz, E.; Jacob, J.S.; Jong, Y.S.; Carino, G.P.; Chickering, D.E.; Chaturvedi, P.; Santos, C.A.; Vijayaraghavan, K.; Montgomery, S.; Bassett, M.; Morrell, C. Biologically erodable microspheres as potential oral drug delivery systems. Nature, 1997, 386(6623), 410-414.
25. Chickering, D.; Jacob, J.; Mathiowitz, E. Poly(fumaric-co-sebacic) microspheres as oral drug delivery systems. Biotechnol. Bioeng., 1996, 52(1), 96-101.
26. Makhlof, A.; Tozuka, Y.; Takeuchi, H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur. J. Pharm. Sci., 2011, 42(5), 445-451.
27. Guan, M.; Zhu, Q.L.; Liu, Y.; Bei, Y.Y.; Gu, Z.L.; Zhang, X.N.; Zhang, Q. Uptake and transport of a novel anticancer drug-delivery system: lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers. Int. J. Nanomedicine, 2012, 7, 1921-1930.
28. Schipper, N.G.; Olsson, S.; Hoogstraate, J.A.; deBoer, A.G.; Vårum, K.M.; Artursson, P. Chitosans as absorption enhancers for poorly absorbable drugs. 2. Mechanism of absorption enhancement. Pharm. Res., 1997, 14(7), 923-929.
29. Ascentiis, A.D.; deGrazia, J.L.; Bowman, C.N.; Colombo, P.; Peppas, N.A. Mucoadhesion of poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are added to the polymer network. J. Control. Release, 1995, 33(1), 197-201.
30. Takeuchi, H.; Yamamoto, H.; Kawashima, Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev., 2001, 47(1), 39-54.
31. Porfire, A.S.; Zabaleta, V.; Gamazo, C.; Leucuta, S.E.; Irache, J.M. Influence of dextran on the bioadhesive properties of poly(anhydride) nanoparticles. Int. J. Pharm., 2010, 390(1), 37-44.
32. Mangal, S.; Pawar, D.; Garg, N.K.; Jain, A.K.; Vyas, S.P.; Rao, D.S.; Jaganathan, K.S. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally. Vaccine, 2011, 29(31), 4953-4962.
33. Chiu, Y.L.; Ho, Y.C.; Chen, Y.M.; Peng, S.F.; Ke, C.J.; Chen, K.J.; Mi, F.L.; Sung, H.W. The characteristics, cellular uptake and intracellular trafficking of nanoparticles made of hydrophobicallymodified chitosan. J. Control. Release, 2010, 146(1), 152-159.
34. Vasir, J.K.; Labhasetwar, V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev., 2007, 59(8), 718-728.
35. Shen, Y.Q.; Zhan, Y.H.; Tang, J.B.; Xu, P.S.; Johnson, P.A.; Radosz, M.; Van Kirk, E.A.; Murdoch, W.J. Multifunctioning pHresponsive nanoparticles from hierarchical self-assembly of polymer brush for cancer drug delivery. AIChE J., 2008, 54(11), 2979-2989.
36. Oldendorf, W.H. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol., 1971, 221(6), 1629-1639.
37. Banks, W.A.; Kastin, A.J. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res. Bull., 1985, 15(3), 287-292.
38. Bobo, R.H.; Laske, D.W.; Akbasak, A.; Morrison, P.F.; Dedrick, R.L.; Oldfield, E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U S A., 1994, 91(6), 2076-2080.
39. Fabel, K.; Dietrich, J.; Hau, P.; Wismeth, C.; Winner, B.; Przywara, S.; Steinbrecher, A.; Ullrich, W.; Bogdahn, U. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer, 2001, 92(7), 1936-1942.
40. Li, M.; Al-Jamal, K.T.; Kostarelos, K.; Reineke, J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano, 2010, 4(11), 6303-6317.
41. Gerweck, L.E.; Seetharaman, K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res., 1996, 56(6), 1194-1198.
42. Fraser, J.R.; Laurent, T.C.; Pertoft, H.; Baxter, E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem. J., 1981, 200(2), 415-424.
43. Wood, K.M.; Wusteman, F.S.; Curtis, C.G. The degradation of intravenously injected chondroitin 4-sulphate in the rat. Biochem. J., 1973, 134(4), 1009-1013.
44. Kissel, T.; Roser, M. Influence of chemical surface-modification on the phagocytic properties of albumin nanoparticles. Proc. Int. Symp. Control. Release Bioact. Mater., 1991, 18, 275-276.
45. Desai, M.P.; Labhasetwar, V.; Walter, E.; Levy, R.J.; Amidon, G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res., 1997, 14(11), 1568-1573.
46. Moghimi, S.M.; Porter, C.J.; Muir, I.S.; Illum, L.; Davis, S.S. Nonphagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem. Biophys. Res. Commun., 1991, 177(2), 861-866.
47. He, C.; Hu, Y.; Yin, L.; Tang, C.; Yin, C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 2010, 31(13), 3657-3666.
48. Dreher, M.R.; Liu, W.; Michelich, C.R.; Dewhirst, M.W.; Yuan, F.; Chilkoti, A. Tumour vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst., 2006, 98(5), 335-344.
49. Perrault, S.D.; Walkey, C.; Jennings, T.; Fischer, H.C.; Chan, W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett., 2009, 9(5), 1909-1915.
50. Owens III, D.E.; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307(1), 93-102.
51. Yang, Z.; Leon, J.; Martin, M.; Harder, J.W.; Zhang, R.; Liang, D.; Lu, W.; Tian, M.; Gelovani, J.G.; Qiao, A.; Li, C. Pharmacokinetics and biodistribution of near-infrared fluorescence polymeric nanoparticles. Nanotechnology, 2009, 20(16), 165101.
52. Stolnik, S.; Illum, L.; Davis, S.S. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev., 1995, 16(2-3), 195-214.
53. Xu, F.; Yuan, Y.; Shan, X.; Liu, C.; Tao, X.; Sheng, Y.; Zhou, H. Long-circulation of hemoglobin-loaded polymeric nanoparticles as oxygen carriers with modulated surface charges. Int. J. Pharm., 2009, 377(1-2), 199-206.
54. Yamaoka, T.; Kuroda, M.; Tabata, Y.; Ikada, Y. Body distribution of dextran derivatives with electric charges after intravenous administration. Int. J. Pharm., 1995, 113(2), 149-157.
55. Zhang, J.S.; Liu, F.; Huang, L. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv. Drug Deliv. Rev., 2005, 57(5), 689-698.
56. Barenholz, Y.C. Doxil® - The first FDA-approved nano-drug: Lessons learned. J. Control. Release, 2012, 160(2), 117-134.
57. Lee, K.S.; Chung, H.C.; Im, S.A.; Park, Y.H.; Kim, C.S.; Kim, S.B.; Rha, S.Y.; Lee, M.Y.; Ro, J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat., 2008, 108(2), 241-250.
58. Sofia, S.J.; Premnath, V.V.; Merrill, E.W. Poly(ethylene oxide) grafted to silicon surfaces: grafting density and protein adsorption. Macromolecules, 1998, 31(15), 5059-5070.
59. Patel, H.M.; Moghimi, S.M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. Adv. Drug Deliv. Rev., 1998, 32(1-2), 45-60.
60. Allen, T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci., 1994, 15(7), 215-220.
61. Panagi, Z.; Beletsi, A.; Evangelatos, G.; Livaniou, E.; Ithakissios, D.S.; Avgoustakis, K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int. J. Pharm., 2001, 221(1-2), 143-152.
62. Calvo, P.; Gouritin, B.; Villarroya, H.; Eclancher, F.; Giannavola, C.; Klein, C.; Andreux, J.P.; Couvreur, P. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci., 2002, 15(8), 1317-1326.
63. Wenger, Y.; Schneider, R.J.2nd; Reddy, G.R.; Kopelman, R.; Jolliet, O.; Philbert, M.A. Tissue distribution and pharmacokinetics of stable polyacrylamide nanoparticles following intravenous injection in the rat. Toxicol. Appl. Pharmacol., 2011, 251(3), 181-190.
64. Semete, B.; Booysen, L.; Kalombo, L.; Ramalapa, B.; Hayeshi, R.; Swai, H.S. Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration. Int. J. Pharm., 2012, 424(1-2), 115-120.
65. Ishihara, T.; Maeda, T.; Sakamoto, H.; Takasaki, N.; Shigyo, M.; Shida, T.; Kiwada, H.; Mizushima, Y.; Mizushima, T. Evasion of the Accelerated Blood Clearance Phenomenon by Coating of Nanoparticles with Various Hydrophilic Polymers. Biomacromolecules, 2010, 11(10), 2700-2706.
66. Stevanovi, M.; Maksin, T.; Petkovi, J.; Filipic, M.; Uskokovi, D. An innovative, quick and convenient labeling method for the investigation of pharmacological behavior and the metabolism of poly(DL-lactide-co-glycolide) nanospheres. Nanotechnology, 2009, 20(33), 335102.
67. Lemarchand, C.; Gref, R.; Couvreur, P. Polysaccharide-decorated nanoparticles. Eur. J. Pharm. Biopharm., 2004, 58(2), 327-341.
68. Yuk, S.H.; Oh, K.S.; Cho, S.H.; Kim, S.Y.; Oh, S.; Lee, J.H.; Kim, K.; Kwon, I.C. Enhancement of the Targeting Capabilities of the Paclitaxel-Loaded Pluronic Nanoparticles with a Glycol Chitosan-Heparin Composite. Mol. Pharm., 2012, 9(2), 230-236.
69. Passirani, C.; Barratt, G.; Devissaguet, J.P.; Labarre, D. Longcirculating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res., 1998, 15(7), 1046-1050.
70. Wang, D.; Shi, J.; Tan, J.; Jin, X.; Li, Q.; Kang, H.; Liu, R.; Jia, B.; Huang, Y. Synthesis, Characterization, and In vivo Biodistribution of (125)I-Labeled Dex-g-PMAGGCONHTyr. Biomacromolecules, 2011, 12(5), 1851-1859.
71. Besheer, A.; Vogel, J.; Glanz, D.; Kressler, J.; Groth, T.; Mäder, K. Characterization of PLGA nanospheres stabilized with amphiphilic polymers: hydrophobically modified hydroxyethyl starch vs pluronics. Mol. Pharm., 2009, 6(2), 407-415.
72. Davis, M.E. Design and development of IT-101, a cyclodextrincontaining polymer conjugate of camptothecin. Adv. Drug Deliv. Rev., 2009, 61(13), 1189-1192.
73. Schluep, T.; Cheng, J.; Khin, K.T.; Davis, M.E. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother. Pharmacol., 2006, 57(5), 654-662.
74. Chang, J.; Jallouli, Y.; Barras, A.; Dupont, N.; Betbeder, D. Chapter 1 - Drug delivery to the brain using colloidal carriers. Prog. Brain Res., 2009, 180, 2-17.
75. Ding, H.; Inoue, S.; Ljubimov, A.V.; Patil, R.; Portilla-Arias, J.; Hu, J.; Konda, B.; Wawrowsky, K.A.; Fujita, M.; Karabalin, N.; Sasaki, T.; Black, K.L.; Holler, E.; Ljubimova, J.Y. Inhibition of brain tumor growth by intravenous poly (beta-L-malic acid) nanobioconjugate with pH-dependent drug release. Proc. Natl. Acad. Sci. U S A., 2010, 107(42), 18143-18148.
76. Schmaljohann, D. Thermo- and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev., 2006, 58(15), 1655-1670.
77. Miller, R.A.; Brady, J.M.; Cutright, D.E. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res., 1977, 11(5), 711-719.
78. Cartier, R.; Kaufner, L.; Paulke, B.R.; Wustneck, R.; Pietschmann, S.; Michel, R.; Bruhn, H.; Pison, U. Latex nanoparticles for multimodal imaging and detection in vivo. Nanotechnology, 2007, 18(19), 195102.
79. Gul, M.O.; Jones, S.A.; Dailey, L.A.; Nacer, H.; Ma, Y.; Sadouki, F.; Hider, R.; Araman, A.; Forbes, B. A poly(vinyl alcohol) nanoparticle platform for kinetic studies of inhaled particles. Inhal. Toxicol., 2009, 21(7), 631-640.
80. Sun, H.; Mei, L.; Song, C.; Cui, X.; Wang, P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials, 2006, 27(9), 1735-1740.
81. Gou, M.; Wei, X.; Men, K.; Wang, B.; Luo, F.; Zhao, X.; Wei, Y.; Qian, Z. PCL/PEG copolymeric nanoparticles: potential nanoplatforms for anticancer agent delivery. Curr. Drug Targets., 2011, 12(8), 1131-1150.
82. Gogolewski, S.; Jovanovic, M.; Perren, S.M.; Dillon, J.G.; Hughes, M.K. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate- co-3-hydroxyvalerate) (PHB/VA). J. Biomed. Mater. Res., 1993, 27(9), 1135-1148.
83. Bergsma, J.E.; Rozema, F.R.; Bos, R.R.; Boering, G.; de Bruijn, W.C.; Pennings, A.J. In vivo degradation and biocompatibility study of in vitro pre-degraded as-polymerized polylactide particles. Biomaterials, 1995, 16(4), 267-274.
84. Tsuji, H.; Ikarashi, K. In vitro hydrolysis of poly(L-lactide) crystalline residues as extended-chain crystallites. Part I: longtermhydrolysis in phosphate-buffered solution at 37°C. Biomaterials, 2004, 25(24), 5449-5455.
85. Moghimi, S.M.; Hunter, A.C. Capture of stealth nanoparticles by the body's defences. Crit. Rev. Ther. Drug Carrier Syst., 2001, 18(6), 527-550.
86. Fernández-Urrusuno, R.; Fattal, E.; Rodrigues, J.M. Jr; Féger, J.; Bedossa, P.; Couvreur, P. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J. Biomed. Mater. Res., 1996, 31(3), 401-408.
87. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42(6), 463-478.
88. Popielarski, S.R.; Hu-Lieskovan, S.; French, S.W.; Triche, T.J.; Davis, M.E. A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug. Chem., 2005, 16(5), 1071-1080.
89. Furumoto, K.; Ogawara, K.; Yoshida, M.; Takakura, Y.; Hashida, M.; Higaki, K.; Kimura, T. Biliary Excretion of Polystyrene Microspheres Depends on the Type of Receptor-Mediated Uptake in Rat Liver. Biochim. Biophys. Acta., 2001, 1526(2), 221-226.
90. Choi, H.S.; Liu, W.; Liu, F.; Nasr, K.; Misra, P.; Bawendi, M.G.; Frangioni, J.V. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol., 2010, 5(1), 42-47.
91. Deen, W.M. What Determines Glomerular Capillary Permeability. J. Clin. Invest., 2004, 114(10), 1412-1414.
92. Choi, H.S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J.P.; Itty, I.B.; Bawendi, M.G.; Frangioni, J.V. Renal clearance of quantum dots. Nat. Biotechnol., 2007, 25(10), 1165-1170.
93. Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Livaniou, E.; Evangelatos, G.; Ithakissios, D.S. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int. J. Pharm., 2003, 259(1-2), 115-127.
94. Seymour, L.W.; Duncan, R.; Strohalm, J.; Kopecek, J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res., 1987, 21(11), 1341-1358.
95. Evans, M.V.; Dowd, S.M.; Kenyon, E.M.; Hughes, M.F.; El-Masri, H.A. A Physiologically Based Pharmacokinetic Model for Intravenous and Ingested Dimethylarsinic Acid in Mice. Toxicol. Sci., 2008, 104(2), 250-260.
96. Danielsen, P.H.; Loft, S.; Kocbach, A.; Schwarze, P.E.; Møller, P. Oxidative damage to DNA and repair induced by Norweigan wood smoke particles in human A549 and THP-1 cell lines. Mutat. Res., 2009, 674(1-2), 116-122.
97. Qiu, L.; Chen, Y.; Gao, M.; Zheng, C.; Zhao, Q. Phagocytic uptake and ROS-mediated cytotoxicity in human hepatic cell line of amphiphilic polyphosphazene nanoparticles. J. Biomed. Mater. Res. A., 2013, 101(1), 285-297.